Literature DB >> 6813492

Comparative pharmacology and biological effects of different gold compounds.

D T Walz, M J DiMartino, D E Griswold.   

Abstract

Auranofin's (AF) physical, chemical, pharmacological, and pharmacokinetic properties differ from those of gold sodium thiomalate (GSTM). AF is lipid soluble, monomeric, nonconductive and is not a potent sulfhydryl reagent. In further contrast to GSTM, AF gold is orally absorbed, exhibits protracted blood levels, is bound to cellular elements of the blood, excreted mainly in the feces, and exhibits less tissue retention. AF is more effective in acute inflammatory models and is a potent inhibitor of lysosomal enzyme release, antibody-dependent cellular cytotoxicity, and superoxide production. AF can suppress antibodies produced in adjuvant arthritic rats and those involved in cytotoxicity reactions; whereas, GSTM is ineffective or immunoenhancing. AF is more effective in stimulating abnormalized cell-mediated immunity. In conclusion, AF is a unique oral chrysotherapeutic agent which can affect cellular and immunopathological events involved in the perpetuation of inflammation and tissue damage.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6813492

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  11 in total

Review 1.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 2.  Current status of disease-modifying drugs in progressive rheumatoid arthritis.

Authors:  J D O'Duffy; H S Luthra
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

3.  Pharmacologic modulation of TNF production by endotoxin stimulated macrophages: in vitro and in vivo effects of auranofin and other chrysotherapeutic compounds.

Authors:  G F Evans; S H Zuckerman
Journal:  Agents Actions       Date:  1989-03

4.  Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy.

Authors:  E H Giannini; E J Brewer; D A Person
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

Review 5.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

6.  A modified mouse air pouch model for evaluating the effects of compounds on granuloma induced cartilage degradation.

Authors:  K M Bottomley; R J Griffiths; T J Rising; A Steward
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

7.  Longterm experience with oral gold in rheumatoid arthritis and psoriatic arthritis.

Authors:  J Dequeker; W Verdickt; G Gevers; K Vanschoubroek
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

8.  Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C.

Authors:  K Hashimoto; C E Whitehurst; T Matsubara; K Hirohata; P E Lipsky
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

9.  Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year, double-blind, comparative multicenter study.

Authors:  M Schattenkirchner; H Bröll; B Kaik; H Müller-Fassbender; R Rau; H Zeidler
Journal:  Klin Wochenschr       Date:  1988-02-15

10.  Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms.

Authors:  Michael Seitz; Jean Valbracht; Jacqueline Quach; Martin Lotz
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.